Abstract:
Th17 cells play an active role in autoimmune diseases. However, the nature of Th17 cells is poorly understood in cancer patients. We studied Th17 cells, the associated mechanisms and clinical significance in 201 ovarian cancer patients. Tumor infiltrating Th17 cells exhibit a polyfunctional effector T cell phenotype; are positively associated with effector cells, and negatively associated with Tregs. Tumor associated macrophages promote Th17 cells through IL-1β, while Tregs inhibit Th17 cells through an adenosinergic pathway. Furthermore, through synergistic action between IL-17 and IFNγ, Th17 cells stimulate CXCL9 and CXCL10 production to recruit effector T cells to the tumor microenvironment. The levels of CXCL9 and CXCL10 are associated with tumor infiltrating effector T cells. The levels of tumor infiltrating Th17 cells, and the levels of ascites IL-17 are reduced in more advanced diseases and positively predict patient outcome. Altogether, Th17 cells may contribute to protective human tumor immunity through inducing Th1-type chemokines and recruiting effector cells to the tumor microenvironment. Inhibition of Th17 cells represents a novel immune evasion mechanism. This study thus provides scientific and clinical rationale for developing novel immune-boosting strategies based on promoting the Th17 cell population in cancer patients.
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Introduction:
Adaptive immunity plays a crucial role in tumor immunosurveillance [1] [2] [3] . It has been shown that tumor infiltrating effector T cells are associated with improved prognoses in multiple human cancers [4] [5] [6] , whereas tumor infiltrating regulatory T (Treg) cells are negatively associated with patient outcome 6, 7 . Th17 cells are newly identified effector CD4 + T cells. Th17 cells and IL-17 play an active role in inflammation and autoimmune diseases [8] [9] [10] [11] [12] [13] [14] [15] . Th17 cells are found in both mouse and human tumors 16, 17 . However, the biological role of Th17 cells is poorly understood in the tumor microenvironment. In this report, we examined the phenotype, cytokine profile, generation, functional relevance, and immunological and clinical predictive values of Th17 cells in 201 patients with ovarian cancers. We provide novel insight into the nature of Th17 cells in the tumor microenvironment in patients with cancer. This information may be useful for designing more effective cancer immunotherapies.
Materials and Methods:
Human subjects. We studied previously-untreated patients with 201 ovarian carcinomas. Survival data was available for 85 patients (Supplementary Table 1) . Patients gave written, informed consent in accordance with the Declaration of Helsinki. The study was approved by the University of Michigan Institutional Review Board.
Cells and tissues.
Cells and tissues were obtained from ascites, blood, lymph nodes and tumors as we described 16, 18, 19 . Immune cells including monocytes, macrophages, myeloid dendritic cells, plasmacytoid dendritic cells and T cell subsets were enriched using paramagnetic beads (StemCell Technology, Vancouver, Canada) and sorted with FACSaria (Becton Dickinson Immunocytometry Systems, San Jose, CA) as we described 16, 18, 19 . Cell purity was > 98% as confirmed by flow cytometry (LSR II, BD).
Flow cytometry analysis (FACS).
For cytokine detection the cells were stimulate with PMA (50 ng/ml, Sigma), ionomycin (1 µM, Sigma) for 4 hours prior staining. Cells were first stained extracellularly with specific antibodies against human CD3, CD4, CD8, CD11b, CD11c, CD14, CD15, CD16, CD19, CD25, CD39, CD45, CD45RO, CD49a, CD49c, CD49d, CD49e, CD56, CD123, CD161, PD-1, CCR4, CCR6, CCR7, CXCR4, HLA-DR, and Annexin V (BD Biosciences), CCR2, CXCR3 and CCR5 (R&D System, Minneapolis, MN), EpCam (StemCell Technology), then were fixed and permeabilized with Perm/Fix solution (E-Biosciences) and finally were stained intracellularly with anti-IL-2, anti-IL-10, anti-IL-17, anti-TNFα, anti-IFN-γ, anti-Granzyme A, antiKi67 and anti-FOXP3 (all from BD Biosciences, except anti-IL-17, eBioscience). Samples were For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From acquired on a LSR II (BD Biosciences) and data were analyzed with DIVA software (BD Biosciences).
Th17 induction and suppression. Fresh peripheral blood and tumor associated CD14 + macrophages were sorted 19 and co-cultured with T cells as indicated for 3-5 days in the presence of anti-CD3 (2.5 -5 µg/ml) and anti-CD28 (1.2-2.5 µg/ml) mAbs (BD Biosciences). Anti-IL-1 receptor (1 µg/ml) was used as indicated (R&D System, Minneapolis, MN). CD4 + CD25 high T cells were sorted from peripheral blood or ovarian cancer tissues 7 . Different concentrations of tumor associated Treg cells were added into the co-culture. In some cases, ARL67156 (50 µM, Sigma Aldrich) was added into the culture as described. T cell phenotype and cytokine profile were determined by FACS or ELISA (R&D, Minneapolis, MN) as we described 16, 18, 19 .
siRNA knockdown of human IL-23 gene expression. HEK293 cells were transfected with a Flag-tagged IL-23 expression plasmid and either a nonfunctional scrambled control siRNA or IL-23-specific siRNA using Lipofectamine 2000 (Invitrogen). After the siRNA treatment, the hIL-23 silencing efficiency was measured by Western-blot using anti-Flag tag (not shown). Blood or tumor associated macrophages were transfected with the siRNA or pmaxGFP vector using
Nucleofector technology (Macrophages Nucleofector Kit, Amaxa, Köln, Germany) as we described 20 . The transfection efficiency reached 60-80% as confirmed by pmaxGFP vector transfection.
Cytokine and chemokine detection. The mRNA levels of cytokines and chemokines were detected by real-time reverse transcriptase polymerase chain reaction (RT-PCR). All experiments were performed using gene-specific primer pairs and SYBR green I (Molecular Probes)
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From fluorescence detection in an Multiplex instrument (Eppendorff). Data analysis is based on the Ct method with normalization of the raw data to housekeeping gene 7, 19 . The protein levels of cytokines and chemokines were detected by either intracellular staining or ELISA kits (all from R&D System, Minneapolis, MN).
Induction of CXCL9 and CXCL10. Th17 cells were polarized from tumor associated T cells (10 6 /ml) for 3 days with tumor associated macrophages (0.5 x 10 6 /ml) in the presence of Th17-inducing cytokine cocktail as we described 20 . The polarized cells were extensively washed with fresh medium and cultured for additional 40 hours. The polarized Th17 cell supernatants were collected. Primary ovarian cancer cells (OC8) or macrophages (1 x 10 5 /ml) 19 were cultured with IL-17 (10 ng/ml), IFNγ (0-50 ng/ml), IL-17 plus IFNγ or 100% Th17 cell-polarized culture supernatants for 2-3 days. In some cases, the neutralizing anti-human IFNγ (2 µg/ml, clone 25723, IgG2b) and anti-IL-17 receptor (2µg/ml, clone 133617, IgG) were added into the culture. The culture supernatants were subjected to measuring CXCL9 and CXCL10 with ELISA kits (R & D).
Migration assay. CD8 + T cell migration was assessed as we described 21 16, 17 . However, the distribution, phenotype and cytokine profile of Th17 cells remain poorly defined in human tumors. We first evaluated the tissue distribution of Th17 cells in ovarian cancer patients. The prevalence of Th17 cells was comparable in tumor draining lymph nodes, cancer patient peripheral blood and normal donor peripheral blood ( Fig 1A) . However, the proportion of Th17 cells was higher in tumors than these compartments ( Fig 1A) . This suggests that Th17 cells may be induced or/and migrate into the tumor microenvironment 16 .
We next examined the phenotype of IL-17 + cells in the tumor microenvironment. We found that IL- Tumor infiltrating Th17 cells expressed high levels of CXCR4, CCR6, CD161 (Fig 1C) , and multiple CD49 integrins (Fig 1D) , but not CCR2, CCR5 and CCR7 ( Fig S1) . The expressed homing molecules may be associated with Th17 cell migration and retention within tumor 20 .
We also analyzed the markers for T cell activation/effector function and immune suppression.
Tumor infiltrating Th17 cells expressed little HLA-DR, CD25, and granzyme B (Fig 1E) . This suggests that Th17 cells may not be conventional effector T cells, and may not mediate effector function through the granzyme B pathway. The B7-H1 receptor, PD-1, may be expressed in functionally exhausted T cells. The B7-H1/PD-1 pathway 22 and FOXP3 + Treg cells 7, 23, 24 For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From contribute to immune suppression in the tumor microenvironment. We found that Th17 cells expressed minimal PD-1 and FOXP3 (Fig 1F) . This indicates that Th17 cells are distinct from Treg cells and functionally exhausted PD-1 + T cells.
We further analyzed the cytokine profile of human tumor infiltrating Th17 cells. IL-10 + and IL-10 -Th17 cells have been observed in mice 25, 26 . We found that Th17 cells expressed minimal IL-10
( Fig 1F) and high levels of polyfunctional effector cytokines including TNFα, IL-2 and IFN-γ ( Fig   1G) . Tumor infiltrating T cells including Th17 cells did not express IL-4 (not shown). Similar cytokine profiles were observed in five other human tumor types studied including colon carcinomas, hepatocellular carcinomas, melanoma, pancreatic cancers, and renal cell carcinomas (not shown). These data indicate that Th17 cells exhibit an effector T cell cytokine profile with polyfunctionality as described in infectious diseases 27, 28 .
Th17 cells and their associations with immune cell subsets in the tumor microenvironment.
Multiple immune cell populations including T cell subsets and antigen presenting cell (APC) subsets infiltrated the tumor microenvironment. We evaluated the relationships between Th17 Fig 2D) .
We further analyzed the relationship between Th17 cells and innate immune cells in the same ovarian cancer ascites. Eosinophils were rarely observed ( Supplementary Fig 2a) . Moderate levels of mast cells (Fig S2B) , neutrophils ( Fig S2C) and NK cells ( Fig 2E) were detected.
However, Th17 cells had no correlation with eosinophils, mast cells and neutrophils ( Fig S2) . We found that the levels of NK cells were higher in patients with high levels of Th17 cells than in patients with low levels of Th17 cells in the same tumor microenvironment (Fig 2E) .
Finally, we analyzed the relationship between Th17 cells and APC subsets. Plasmacytoid dendritic cells (PDCs) 21 , myeloid dendritic cells (MDCs) and macrophages are the main APC populations in ovarian cancer 19 ( Fig S3A) . These three APC subsets were found in the tumor ascites and tumor (Fig S3A) . However, there were no quantitative correlations between Th17 cells, and myeloid DCs, (Fig S3B) , plasmacytoid DCs ( Fig S3C) and macrophages ( Fig S3D) . We further investigated the functional association between Th17 cells and APC subsets in the subsequent studies.
Altogether, the data demonstrate that Th17 cells are quantitatively and positively correlated with NK cell-mediated innate immunity and adaptive T cell immunity.
Induction and suppression of Th17 cell development in the tumor microenvironment.
Th17 cells are basically found in the tumor microenvironment in patients with cancer 16 . APCs contribute to T cell polarization. We investigated the role of tumor associated macrophages (TAMs), plasmacytoid DCs and myeloid DCs in Th17 cell induction in ovarian cancer. We found that tumor associated plasmacytoid DCs had minimal effects on Th17 cell induction (Fig S4) .
TAMs and myeloid DCs isolated from ovarian cancers stimulated Th17 cell induction from memory T cells, and not from naïve T cells ( Fig S4, and Fig 3A) . TAMs were more efficient than normal macrophages (Mφs) in eliciting T cell IL-17 production, and the induction was dose dependent ( Fig   3B) . Macrophages outnumbered myeloid DCs in ovarian cancer 19, 21 ( Fig S3) , and were superior to inducing Th17 cells than myeloid DCs (Fig S4 and Fig 3B) 
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. Our subsequent studies focused on tumor associated macrophages.
We investigated the mechanism by which TAMs induce Th17 cells. We found that TAMs expressed higher levels of IL-1β and IL-23p19 mRNA, as compared to normal macrophages ( Fig   3C) . Blockade of IL-1, but not IL-6 and TGFβ consistently and largely reduced TAM-mediated induction of Th17 cells ( Fig 3D, and not shown) . Blocking IL-23 with specific siRNA further helped reduce Th17 cell induction (Fig 3D) . Our data suggest that IL-1β plays a predominant role in TAMmediated Th17 cell induction in patients with ovarian cancer.
Since TAMs are potent Th17 cell inducers (Fig 3A, B, D) , we examined why there were limited numbers of Th17 cells in the tumor microenvironment (Fig 1) . We hypothesized that tumor associated Treg cells might suppress Th17 cell development. To test this hypothesis, we first stimulated T cells with TAMs in the presence of tumor associated Treg cells. Treg cells suppressed Th17 cells and T cell IL-17 production in a dose dependent manner (Fig 3E, F) .
We further studied the mechanism by which Tregs suppressed Th17-induction. Tumor associated Treg cells highly expressed CD39 (Fig S5A, B) , an ectonucleotidase which converts ATP into adenosine. Mouse Treg cells may mediate T cell suppression through adenosine induction 30, 31 .
We found that ARL67156, a structural analogue of ATP and an ectonucleotidase inhibitor, partially but significantly recovered T cell IL-17 production suppressed by tumor associated Treg cells ( Fig   3G) . These data indicate that Th17 cell development is partially suppressed by tumor associated
Treg cells through the adenosinergic pathway.
Th17, and Th1, Th2 type-cytokines and chemokines.
To further examine the relationships between Th17 cells and the types of immune responses in the ovarian cancer microenvironment, we quantified numerous representative cytokines and chemokines associated with Th17, Th1 and Th2 type-responses in the ovarian cancer ascites.
Th17 cells were the only cell type expressing IL-17 in the ovarian cancer ascites. We detected variable levels of IL-17 in ascites fluid. Interestingly, the levels of IL-17 were positively correlated with IL-1β and IL-1α (Fig S6A, B ), but not with TGFβ, IL-6 ( Fig S6C and not shown) , IL-21 ( Fig   S6) , IL-23 ( Fig S6E) and PGE2 (Fig S6F) . IL-23 protein was barely detectable in most of the samples tested (Fig S6E) . All these molecules have been reported to be associated with Th17 cell [8] [9] [10] [11] [12] [13] [14] [15] 32 . Given that the levels of IL-1α were less than 5 pg/ml (Fig S6B) , the data further support that IL-1β plays a selective and crucial role in Th17 cell induction in the ovarian cancer microenvironment (Fig 3C, D) .
Cytokines associated with Th1 and Th2-type responses including IL-12, IL-2 and IL-4 were less than 10 pg/ml in ovarian cancer ascites. IL-17 has been reported to induce tumor angiogenesis 33, 34 . Consistent with previous reports, high levels of angiogeneic factors including IL-8 and VEGF were detected in the ascites. However, IL-17 was not correlated with these angiogeneic molecules (Fig S7) .
In addition to cytokines, we further evaluated the relationship between IL-17 and chemokines associated with Th1-type response including CXCL9, CXCL10, and with Th2-type response including CXCL12 and CCL22. Interestingly, we observed a significant positive correlation between IL-17, CXCL9 and CXCL10 (Fig 4A, B) . Although we detected high levels of CXCL12 and CCL22, IL-17 had no association with these chemokines (Fig S8) . The data indicate that in addition to Th1-type effector T cells and NK cells (Fig 2) , Th17 cells and IL-17 are correlated with Th1-type chemokines in the ovarian cancer microenvironment.
In addition, we examined the mechanistic relationship between Th17 cells and tumor immunity.
Th17 cells or IL-17 had no direct effects on primary ovarian cancer cell proliferation and apoptosis ( Fig S9) . As Th17 cells are positively correlated with Th1-type chemokines and effector T cells, we hypothesized that Th17 cells induce Th1-type chemokines, and in turn recruit Th1-type effector T cells into tumor microenvironment. To test this hypothesis, we initially studied the effects of Th17
on Th1-type chemokine production. We found that IFNγ and IL-17 synergistically induced the production of CXCL9 and CXCL10 by primary ovarian cancer cells and macrophages (Fig 4C, D, and not shown). Consistent with this observation, real-time PCR revealed that the levels of IL-17 were positively correlated with that of CXCL9 and CXCL10 in the same tumor tissues (Fig S10) . In further support, the supernatants derived from Th17 cells induced high levels of CXCL10 production. This production was blocked by neutralizing anti-human IFNγ and anti-IL-17 (Fig 4E) .
These data indicate that Th17 cells induce Th1-type chemokine production.
Th17, Th1 type-chemokines and effector T cell trafficking.
Tumor associated effector CD8 + T cells highly expressed CXCR3, the receptor for CXCL9 and CXCL10 (Fig 5A) . Tumor associated effector CD8 + T cells efficiently migrated toward tumor ascites in a dose dependent manner. The migration was reduced by neutralizing anti-CXCR3 ( Fig   5B) . We also quantified the number of tumor infiltrating CD8 + T cells by immunofluorescence staining. The mRNA levels of CXCL9 and CXCL10 were positively correlated with tumor infiltrating CD8 + T cells in the same tumor (Fig 5C, D) . Furthermore, when we divided tumor tissues into two groups based on the median levels of IL-17, we observed that the levels of tumor ascites IL-17
were positively associated with tumor infiltrating CD8 + T cells (Fig 5E, F) . Altogether, the data support the notion that Th17 cells induce Th1-type chemokines through IL-17 and IFNγ, and in turn recruit Th1-type effector T cells and NK cells into tumor microenvironment.
Increased tumor associated IL-17 predicts improved patient survival.
Our current data suggest that Th17 cells may contribute to protective tumor immunity in ovarian cancers. IL-17 is released into the tumor environment consisting of the abdominal cavity. IL-17
was detectable in all the ovarian cancer ascites we evaluated (Fig 4A, B) . We analyzed the impact of IL-17 levels in the ascites on patient survival.
There was a significant association between ascites IL-17 levels and survival in the group as a whole (n = 85, P = 0.0001), and also for patients in stage II/III (n = 57, P = 0.01) and stage IV (n = 28, P = 0.005). Tumor ascites IL-17 was a significant predictor of death hazard (95% CI, P =0.0003) even after controlling for surgical debulking and other parameters using a Cox proportional hazards model (Fig 6, Table 1 and S Table 1 ).
As an alternative analysis, patients were divided into two groups based on the median values of IL-17 (220 pg/ml). Survival functions were significantly different for the 2 groups ( Fig 5A) Furthermore, when the analyses were stratified by stage, we found significant association between ascites IL-17 and survival for patients in stage III (n = 52, P = 0.01) (Fig 6B) as well as
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From stage IV disease (n = 28, P = 0.005) (Fig 5C) . We additionally found that patients in stage IV had significantly reduced IL-17 in ascites compared to those in stage III ( Fig 6D) , we demonstrated for the first time that human tumor associated Treg cells inhibit Th17 cells with a similar molecular mechanism. In addition to multiple modes of immune suppressive mechanisms demonstrated in the tumor microenvironment [49] [50] [51] [52] [53] , as human Th17 cells likely mediate protective tumor immunity, inhibition of Th17 cell development may be a novel immunoediting mechanism for tumor to escape tumor immunity.
In summary, we have extensively defined the nature of Th17 in the human tumor microenvironment. Our data provides immunological and clinical evidence linking Th17 cells to immune protection in human cancer, and suggests that inhibition of Th17 cell development is a novel immune evasion mechanism. This study thus provides the rationale for developing novel immune-boosting strategies based on promoting the Th17 cell population in cancer patients.
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